We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Take da money

12 May 2011 By Peter Thal Larsen

Buying Switzerland’s Nycomed for a possible $14 bln would refresh the Japanese pharma group’s pipeline and boost exposure to fastgrowing economies. With almost $11 bln of cash, financing isn’t a problem. And a deal might just stack up if Nycomed’s performance is about to turn.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)